Technical Analysis for INM - InMed Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Upper Bollinger Band Walk | Strength | -2.76% | |
| Wide Bands | Range Expansion | -2.76% | |
| Upper Bollinger Band Touch | Strength | -2.76% | |
| 180 Bullish Setup | Bullish Swing Setup | -0.24% | |
| Stochastic Reached Overbought | Strength | -0.24% | |
| Upper Bollinger Band Walk | Strength | -0.24% |
| Alert | Time |
|---|---|
| Bullish 180 Entry | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
| Down 5% | 2 days ago |
| Down 3% | 2 days ago |
| Up 5% | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2024
InMed Pharmaceuticals Inc. Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Disease Rare Diseases Cannabis Pharmacology Dermatology Stage Pharmaceutical Glaucoma Toxicology Genodermatoses Treatment Of Glaucoma Cannabinoid Epidermolysis Bullosa Ocular Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.41 |
| 52 Week Low | 0.1207 |
| Average Volume | 641,498 |
| 200-Day Moving Average | 0.39 |
| 50-Day Moving Average | 0.67 |
| 20-Day Moving Average | 1.31 |
| 10-Day Moving Average | 2.34 |
| Average True Range | 0.44 |
| RSI (14) | 81.17 |
| ADX | 41.53 |
| +DI | 67.55 |
| -DI | 9.73 |
| Chandelier Exit (Long, 3 ATRs) | 4.09 |
| Chandelier Exit (Short, 3 ATRs) | 1.53 |
| Upper Bollinger Bands | 4.94 |
| Lower Bollinger Band | -2.32 |
| Percent B (%b) | 0.9 |
| BandWidth | 554.56 |
| MACD Line | 1.01 |
| MACD Signal Line | 0.54 |
| MACD Histogram | 0.4648 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.59 | ||||
| Resistance 3 (R3) | 4.58 | 4.46 | 4.53 | ||
| Resistance 2 (R2) | 4.46 | 4.36 | 4.46 | 4.51 | |
| Resistance 1 (R1) | 4.34 | 4.31 | 4.40 | 4.35 | 4.49 |
| Pivot Point | 4.22 | 4.22 | 4.25 | 4.22 | 4.22 |
| Support 1 (S1) | 4.10 | 4.12 | 4.16 | 4.11 | 3.97 |
| Support 2 (S2) | 3.98 | 4.07 | 3.98 | 3.95 | |
| Support 3 (S3) | 3.86 | 3.98 | 3.93 | ||
| Support 4 (S4) | 3.87 |
